Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pardoprunox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 19/20 | 0.58 |
| ▸ | HTR1A known ✓ | P08908 | 15/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pardoprunox SCHEMBL29358670 | 1.00 | DRD2 (0.58) | DRD2HTR1AHTR2AMCHR1SLC6A4 | |
| Pardoprunox SCHEMBL1584476 | 0.99 | DRD2 (0.57) | DRD2HTR1AHTR2AMCHR1SLC6A4 | |
| Pardoprunox SCHEMBL30730668 | 0.99 | DRD2 (0.57) | DRD2HTR1AHTR2AMCHR1SLC6A4 | |
| Pardoprunox SCHEMBL1584623 | 0.97 | DRD2 (0.56) | DRD2HTR1AHTR2AMCHR1SLC6A4 | |
| Pardoprunox SCHEMBL1584493 | 0.92 | DRD2 (0.53) | DRD2HTR1AHTR2AMCHR1SLC6A4 | |
| SCHEMBL13239009 | 0.85 | DRD2 (0.57) | DRD2HTR1AHTR2AMCHR1SLC6A4 | |
| SCHEMBL13533093 | 0.85 | DRD2 (0.64) | DRD2HTR1AHTR2AMCHR1SLC6A4 | |
| SCHEMBL1443282 | 0.84 | DRD2 (0.56) | DRD2HTR1AHTR2AMCHR1 | |
| Hydrochloric Acid SCHEMBL1886136 | 0.82 | DRD2 (0.55) | DRD2HTR1AHTR2AMCHR1 | |
| SCHEMBL8260753 | 0.82 | PSMB8 (0.47) | DRD2HTR1AHTR2AMCHR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488181-A1 | POLYMORPHS OF PARDOPRUNOX | Abbott Healthcare Products B.V. (NL) | 2012-08-22 | — | — | EP | claimed |
| WO-2011045267-A1 | POLYMORPHS OF PARDOPRUNOX | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-04-21 | — | — | WO | claimed |
| US-20110086862-A1 | POLYMORPHS OF PARDOPRUNOX | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-04-14 | — | — | US | claimed |
| US-7596407-B2 | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2009-09-29 | — | — | US | claimed |
| EP-1742632-A2 | TRANSDERMAL IONTOPHORETIC DELIVERY OF PIPERAZINYL-2(3H)-BENZOXAZOLONE COMPOUNDS | Solvay Pharmaceuticals B.V. (NL) | 2007-01-17 | — | — | EP | claimed |
| WO-2005107754-A2 | TRANSDERMAL IONTOPHORETIC DELIVERY OF PIPERAZINYL-2(3H)-BENZOXAZOLONE COMPOUNDS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-11-17 | — | — | WO | claimed |
| US-20050234389-A1 | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-10-20 | — | — | US | claimed |
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | PHARMACIA CORPORATION (US) | 2004-07-29 | — | — | US | claimed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| US-10555958-B2 | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2020-02-11 | — | — | US | disclosed |
| US-20170239281-A1 | COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170239281-A1 | COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| CN-102784111-A | Sustained-release preparation of dopamine receptor agonist drugs | Shandong luye pharmaceutical co ltd | 2012-11-21 | — | — | CN | disclosed |
| EP-2488181-A1 | POLYMORPHS OF PARDOPRUNOX | Abbott Healthcare Products B.V. (NL) | 2012-08-22 | — | — | EP | disclosed |
| EP-1742632-A2 | TRANSDERMAL IONTOPHORETIC DELIVERY OF PIPERAZINYL-2(3H)-BENZOXAZOLONE COMPOUNDS | Solvay Pharmaceuticals B.V. (NL) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006061379-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| EP-0908458-B1 | Substituted pyridylmethylpiperazine and piperidine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | DUPHAR INT RES (NL) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005107754-A2 | TRANSDERMAL IONTOPHORETIC DELIVERY OF PIPERAZINYL-2(3H)-BENZOXAZOLONE COMPOUNDS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-11-17 | — | — | WO | disclosed |
| US-20050234389-A1 | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-10-20 | — | — | US | disclosed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | HTR2A, HTR1A, TPH2 | DRD2 216/4885HTR1A 2/4885HTR2A 1/4885 |
| US-10555958-B2 | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals | SLC5A2, SLC5A1, SLC6A3 | DRD2 56/4885HTR1A 171/4885HTR2A 153/4885 |
| US-20170239281-A1 | COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS | SLC5A2, SLC5A1, SLC6A3 | DRD2 56/4885HTR1A 171/4885HTR2A 153/4885 |
| US-20110086862-A1 | POLYMORPHS OF PARDOPRUNOX | DRD2, HTR1A, HTR2C | DRD2 1/4885HTR1A 2/4885HTR2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.